![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 29, 20281-20286, July 16, 1999
From the Department of Molecular Pharmacology, Stanford University School of Medicine, Stanford, California 94305
| |
ABSTRACT |
|---|
|
|
|---|
We used mouse hepatoma (Hepa1c1c7) cells to study
the role of the serine/threonine kinase Akt in the induction of
GLUT1 gene expression. In order to selectively turn on the
Akt kinase cascade, we expressed a hydroxytamoxifen-regulatable form of
Akt (myristoylated Akt1 estrogen receptor chimera (MER-Akt1)) in the
Hepa1c1c7 cells; we verified that hydroxytamoxifen stimulates MER-Akt1
activity to a similar extent as the activation of endogenous Akt by
insulin. Our studies reveal that stimulation of MER-Akt1 by
hydroxytamoxifen induces GLUT1 mRNA and protein accumulation to
levels comparable to that induced by insulin; therefore, activation of
the Akt cascade suffices to induce GLUT1 gene expression in
this cell system. Furthermore, expression of a kinase-inactive Akt
mutant partially inhibits the response of the GLUT1 gene to
insulin. Additional studies reveal that the induction of GLUT1 mRNA
by Akt and by insulin reflects increased mRNA synthesis and not
decreased mRNA degradation. Our findings imply that the
GLUT1 gene responds to insulin at the transcriptional level
and that Akt mediates a step in the activation of GLUT1
gene expression in this system.
The members of a family of six membrane proteins, known as the
glucose transporters (GLUT1-5 and
GLUT7),1 facilitate glucose
uptake into mammalian cells (reviewed in Refs. 1 and 2). Glucose uptake
is critical for maintaining intracellular ATP levels, and cells have
evolved several strategies for regulating this process. For example, in
fat and muscle, insulin stimulates the rapid translocation of the GLUT4
protein from an intracellular site to the plasma membrane, where it
functions (3). In other tissues and cells, long term insulin treatment
stimulates glucose uptake by increasing GLUT1 gene
expression, thereby providing more transporter proteins to the cell (4,
5). The GLUT1 gene also responds to other stimuli. For
example, hypoxia induces GLUT1 gene expression (6-8); this
response may help protect neurons from glucose starvation and death
during brain ischemia (9). In addition, increased GLUT1 gene
expression is associated with oncogenic transformation of various cell
types (10-12). These observations imply that the regulation of
GLUT1 gene expression is relatively complex and may involve
several converging signaling pathways.
The GLUT1 gene constitutes an interesting system for
analyzing the mechanism by which insulin alters specific gene
expression. Insulin binds to a cell surface receptor and activates an
intrinsic receptor tyrosine kinase, a process that ultimately
stimulates two major signaling cascades (13). One cascade leads to the activation of MAP kinase and the phosphorylation of transcription factors (14). The second cascade involves phosphatidylinositol (PI)-3
kinase (15) and numerous potential downstream effectors, including the
serine/threonine kinase Akt (also called protein kinase B (PKB)) (16).
Akt activity reflects contributions from three distinct isozymes
(Akt1-3), which are regulated primarily by phosphorylation (16).
Expression of a constitutively active Akt1 can mimic several
nontranscriptional responses to insulin, including inhibition of
glycogen synthase kinase-3, activation of the p70 ribosomal S6 kinase,
stimulation of GLUT4 translocation and glucose uptake, stimulation of
protein synthesis, and inhibition of apoptosis (13, 16).
It is less clear whether Akt can mediate transcriptional responses to
insulin (17). Several reports provide conflicting data on this point
(18-22). To further address this issue, we have asked here whether Akt
can induce GLUT1 gene transcription in mouse hepatoma
(Hepa1c1c7) cells. We find that activation of the Akt1 kinase suffices
to induce GLUT1 transcription to an extent similar to that
induced by insulin. Moreover, expression of an inactive Akt1 partially
inhibits the ability of insulin to stimulate GLUT1 gene
expression. These results imply that Akt is a downstream effector of
insulin action in inducing GLUT1 gene transcription in this
cell system.
Materials--
Minimum Eagle's medium and G418 were from Life
Technologies, Inc., and other cell culture media were from UCSF Cell
Culture Facility (San Francisco, CA). Total RNA was isolated using the RNeasy kit from Qiagen (Chatsworth, CA). The reverse transcription polymerase chain reaction kit was from Stratagene (La Jolla, CA). The
primers for the GLUT1 and Plasmid Constructs--
The retroviral plasmids coding for
HA-tagged MER-Akt1 and the inactive HA-tagged Akt1-S473A/T308A mutant
were as described (20, 25), except that both constructs were expressed
using the pWZL-neo retroviral vector (a gift from Dr. Garry P. Nolan, Stanford, CA).
Cell Culture--
Hepa1c1c7 cells stably transfected with
MER-Akt1-pWZL-neo, Akt1-S473A/T308A-pWZL-neo, or empty vector alone
(pWZL-neo) were grown in 6-well Nunclon dishes (Nalge Nunc
International, Roskilde, Denmark) in Retroviral Infection--
Hepa1c1c7 cells were infected with
MER-Akt1 pWZL-neo, Akt1-S473A/T308A-pWZL-neo, or empty vector alone
(pWZL-neo) as described previously (25); selection was performed in 2 mg/ml G418.
Isolation of Membrane Proteins and Western Blots of
GLUT1--
Cells were scraped in 2 ml of buffer (50 mM
Hepes, pH 7.5, 150 mM NaCl, 0.5 mM EDTA, 1 mM dithiothreitol, 1 mM benzamidine, 1 mM phenylmethylsulfonyl fluoride), homogenized by 10 push/pull cycles using a 23 gauge needle and a 3-ml syringe, and the
membranes were spun down at 4 °C for 1 h at 100,000 × g in a tabletop microcentrifuge (Beckman). The membrane
pellet was washed once in the same volume of buffer, resolubilized in
buffer containing 0.1% (v/v) Triton X-100, and analyzed by SDS-PAGE.
The proteins were transferred to nitrocellulose membranes (2 h, 300 mA
tank blotting) and the transfer was verified by Ponceau red staining
before blocking the membrane with 3% bovine serum albumin in
Tris-buffered saline-Tween (0.1%). The membranes were then incubated
for 2 h in the first antibody (usually 1:5000 in 3% bovine serum
albumin/Tris-buffered saline-Tween), washed briefly and incubated for
another 1 h in secondary antibody (1:5000 in 3% fat-free
milk/Tris-buffered saline-Tween). After extensive washing
(Tris-buffered saline-Tween) the signal was visualized by
chemiluminescence using a system containing luminol and coumaric acid.
Akt Assays--
The Akt kinase assay using GSK-3 peptide
(GRPRTSSFAEG) as substrate was performed as described previously (25).
In brief, cells were lysed in 400 µl of lysis buffer/well. Endogenous
Akt1, Akt3, or expressed HA-tagged MER-Akt1 was immunoprecipitated from the lysates using protein A-Sepharose beads that were preabsorbed with
anti-Akt1 or Akt3 PH-domain antiserum or monoclonal anti-HA antibody
(12CA5). Nonspecific background was measured by incubating lysates with
protein A-Sepharose beads that were preabsorbed with either normal
rabbit serum or normal mouse IgG. Following the kinase reaction, the
phosphorylated peptide was separated from free
[ Generation of the GLUT1 and Extraction of Total RNA and Northern Blots--
Total RNA was
extracted from Hepa1c1c7 cells and examined by agarose gel
electrophoresis. The RNA concentration was determined spectrophotometrically (Beckman DU 640). Five µg of total RNA/lane were separated on a 1% (w/v) denaturing agarose/formaldehyde gel (26)
and transferred overnight in 20× SSC onto nylon membranes. The
membranes were air-dried and the bound RNA UV-cross-linked (1200 µJ
in 1 min) using a Stratalinker (Stratagene, La Jolla, CA). The blots
were probed overnight at 65 °C, visualized by autoradiography, and
quantified using a PhosphorImager and the Imagequant software (Molecular Dynamics, Sunnyvale, CA).
Nuclear Run-on Assays--
The assays were performed as
described (7). In short, confluent Hepa1c1c7 cells (10-cm dishes)
stably expressing MER-Akt1 were serum-starved overnight and treated
with insulin, hydroxytamoxifen, or vehicle (ethanol) for another 16-18
h in serum-free medium. The cells from 1 plate were then washed once
with ice-cold PBS and scraped into 8 ml of lysis buffer/plate (10 mM Tris, pH 7.4, 10 mM NaCl, 3 mM
MgCl2, 0.5% Nonidet P-40). Nuclei were spun down for 5 min
at 1000 × g, resuspended in 100 µl of storage buffer (20 mM Tris, pH 8.1, 100 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol, 1 mM
phenylmethylsulfonyl fluoride, 50% v/v glycerol), flash-frozen in
liquid nitrogen, and stored at Induction of Akt Activity and GLUT1 mRNA in Mouse Hepatoma
Cells--
We found that insulin produces substantial increases in
both Akt activity and GLUT1 mRNA in mouse hepatoma (Hepa1c1c7)
cells. Therefore, we used this cell system to explore the relationship between Akt activation and GLUT1 gene expression. In Hepa
1c1c7 cells, insulin induced Akt1 activity with an EC50 of
about 1 nM (Fig.
1A); induction was maximal
following a 20-min exposure (data not shown). Insulin induced GLUT1
mRNA with an EC50 of about 10 nM (Fig.
1B); the response was maximal after about 18 h (data not shown). The approximately 10-fold higher concentration of insulin
required for GLUT1 mRNA induction presumably results from the
longer incubation time required for this latter response. For example,
we observed that, at a starting concentration of 10 nM,
>90% of the input insulin was degraded after 9 h of incubation with the cells (data not shown). Both responses exhibit sensitivities to insulin similar to those reported for other systems (5, 20, 27).
These findings suggested that Akt activation might be linked
mechanistically to GLUT1 gene expression; therefore, we
performed experiments designed to test this possibility.
Expression of a Regulatable Akt1--
To identify a possible
relationship between Akt activity and GLUT1 gene expression,
we infected Hepa1c1c7 cells with a retroviral vector encoding MER-Akt1,
which is a hydroxytamoxifen-regulatable version of an epitope-tagged
Akt1 (25). We verified expression of the protein by treating cells with
hydroxytamoxifen, lysing them, immunoprecipitating the epitope-tagged
MER-Akt1, and measuring its enzymatic activity. Our findings
demonstrate that hydroxytamoxifen causes a rapid and sustained increase
in Akt enzymatic activity in cells that express MER-Akt1 (Fig.
2A); however, the increase does not occur in uninfected cells (data not shown). The time course of
MER-Akt1 activation by hydroxytamoxifen is only slightly slower then
the time course of endogenous Akt1 activation by insulin (Fig.
2B). The maximal activity of hydroxytamoxifen-stimulated MER-Akt1 in the anti-HA antibody precipitates (about 70,000 cpm) (Fig.
2A) is about 3 times the maximal activity of
insulin-stimulated endogenous Akt1 (Fig. 2B). Immunoblotting
studies of total lysates indicate that the MER-Akt1 is expressed at a
level comparable to that of the endogenous Akt1 (Fig. 2A,
inset). Because Akt has three distinct isoforms, we also measured
the activity of endogenous Akt2 and Akt3 in Hepa1c1c7 cells after
stimulation with insulin. We observed that insulin stimulates
endogenous Akt3 activity (Fig. 2B, inset) to a level that is
about twice the maximal amount of hydroxytamoxifen-stimulated MER-Akt1
activity (Fig. 2A), whereas these cells contain only a low
level of Akt2 activity (data not shown). These results indicate that
the level of hydroxytamoxifen-stimulated MER-Akt1 activity in the
infected cells is about half the level of insulin-stimulated total Akt
activity in the parental cells. Therefore, the findings described below
using cells containing hydroxytamoxifen-stimulated MER-Akt1 do not
reflect artifacts related to overexpression of Akt enzyme activity.
To demonstrate a link between Akt activity and GLUT1 gene
expression, we asked whether hydroxytamoxifen induces GLUT1 mRNA accumulation in cells containing MER-Akt1. Our findings reveal that
hydroxytamoxifen induces GLUT1 mRNA and GLUT1 protein to levels
comparable to those that insulin induces in these cells (Fig.
3A). In control cells infected
with an empty virus, hydroxytamoxifen does not induce GLUT1 mRNA or
protein (Fig. 3A). We also measured the kinetics of
hydroxytamoxifen-induced GLUT1 mRNA and protein accumulation; both
responses reach plateaus after 24 h (Fig. 3, B and
C). These kinetics are similar to those observed with
insulin (data not shown). In addition, induction of GLUT1 mRNA and
Akt1 activity both occur over the same concentration range of
hydroxytamoxifen (Fig. 4). These
findings, together with the observation that hydroxytamoxifen does not
induce GLUT1 mRNA in cells that do not contain MER-Akt1, reveal
that stimulation of Akt1 activity leads to an increase in GLUT1
mRNA. The simplest interpretation of these observations is that
Akt1 regulates GLUT1 gene expression.
Expression of an Enzymatically Inactive Akt1--
To further
examine the potential link between insulin, Akt, and GLUT1
gene expression, we expressed an enzymatically inactive Akt1 mutant in
Hepa1c1c7 cells. Immunoblotting studies indicate that the mutant Akt1
is expressed at levels that are comparable to those of the endogenous
Akt1 protein (Fig. 5A).
Induction experiments reveal that, in cells that express the mutant
Akt1, the GLUT1 gene exhibits about a 50% reduction in its
response to insulin (Fig. 5B). In contrast, expression of
the mutant Akt1 had no effect on the response of the GLUT1
gene to hypoxia (data not shown). This selective inhibitory effect of
the Akt mutant on the response of the GLUT1 gene to insulin
provides additional evidence that Akt is a component of the
insulin-responsive signaling pathway that regulates GLUT1
gene expression in Hepa1c1c7 cells.
Insulin and Akt Induce GLUT1 Transcription--
In principle,
insulin and Akt could induce GLUT1 mRNA accumulation by increasing
mRNA synthesis or by decreasing mRNA degradation. To
distinguish between these possibilities, we used actinomycin D to
inhibit mRNA synthesis, and we measured the half-life of GLUT1
mRNA in Hepa1c1c7 cells that stably express MER-Akt1. Our findings
reveal no differences in the rates of GLUT1 mRNA decay in
uninduced, insulin-induced, or hydroxytamoxifen-induced cells (Fig.
6). In all three cases, the half-life of
GLUT1 mRNA is about 4 h. Therefore, these findings reveal no
evidence for GLUT1 mRNA stabilization after hydroxytamoxifen or
insulin treatment.
To test directly whether insulin and Akt activation stimulate
GLUT1 gene transcription, we performed nuclear run-on
experiments using Hepa1c1c7 cells that stably express MER-Akt1. Our
findings indicate that insulin and hydroxytamoxifen both increase
GLUT1 transcription about 3-fold (Fig.
7). These findings, together with the
lack of change in mRNA degradation, imply that the induction of
GLUT1 gene expression arises primarily at the level of
transcription.
In mammalian cells, a family of GLUT proteins mediates glucose
uptake, thereby profoundly influencing cellular metabolism (1-3). The
GLUT1 gene, which encodes the most widely expressed glucose
transporter, responds to several chemical and hormonal stimuli and
makes an important contribution to the maintenance of intracellular
homeostasis. Thus, an understanding of the events that control
GLUT1 gene expression may provide important insights into
the molecular mechanisms by which cells adapt to changes in their environment.
Here, we show that an increase in GLUT1 gene transcription
substantially accounts for the accumulation of GLUT1 mRNA and
protein that accompanies exposure of mouse hepatoma cells to insulin. Furthermore, we demonstrate that elevating Akt activity leads to
increased GLUT1 transcription and to mRNA and protein
accumulation in the absence of insulin. Finally, we show that
expression of a kinase inactive Akt1 inhibits the ability of insulin to
induce GLUT1 mRNA. Therefore, we infer that an increase in Akt
activity is an important event in the signaling pathway through which
insulin regulates GLUT1 gene expression.
Our findings are consistent with and extend prior observations that
expression of a constitutively active Akt1 increases both the GLUT1
protein in 3T3-L1 adipocytes and the GLUT3 protein in L6 skeletal
muscle cells (28, 29). Our observations are also consistent with a
prior report implicating the p21ras protein in insulin-induced
GLUT1 gene expression (30) because p21ras can
activate the PI 3-kinase/Akt pathway (31). In addition, our work is
consistent with studies that implicate the mammalian target of
rapamycin (mTOR) in the induction of the GLUT1 mRNA by insulin (7,
32) because Akt regulates mTOR (33), and we find that rapamycin
inhibits the insulin-induced increase in GLUT1 mRNA in the
Hepa1c1c7 cells.2 However,
our findings are not consistent with a recent report that wortmannin,
an inhibitor of the PI 3-kinase/Akt pathway, fails to inhibit the
insulin-stimulated increase in GLUT1 gene transcription in
L6 skeletal muscle cells (32). Perhaps these findings reflect
differences in cell type, because the p21ras protein also does
not appear to play a role in insulin-induced GLUT1 gene
transcription in L6 cells (34). It is also possible that the lack of
effect of wortmannin is due to the instability of this molecule. For
example, we find that LY294002, another PI 3-kinase inhibitor (35),
inhibits induction of GLUT1 mRNA by insulin in Hepa1c1c7
cells.2
From a mechanistic standpoint, we envision that Akt stimulates
GLUT1 transcription via phosphorylation of a particular
protein(s). The target for phosphorylation might be a specific
transcription factor(s) or a signaling component(s) that functions
prior to the formation of a transcriptional complex at the GLUT1
promoter. The GLUT1 gene contains multiple DNA elements that
enhance transcription in concert with their cognate binding proteins.
Akt might influence GLUT1 gene expression by phosphorylating
a protein that binds to the serum-responsive element, the
cAMP-responsive element, and/or the
12-O-tetradecanoylphorbol-13-acetate-responsive element (26). For example, Akt might regulate GLUT1 gene expression by its recently described ability to phosphorylate and regulate CREB
(cAMP response element-binding protein) (36). Alternatively, insulin
might regulate GLUT1 gene expression via the
hypoxia-responsive element and its cognate DNA-binding proteins
hypoxia-inducible factor-1 Our studies demonstrate that activation of the Akt kinase cascade is
sufficient to induce GLUT1 mRNA and protein accumulation via an
increase in GLUT1 gene transcription. The increase in GLUT1 activity may in part account for the ability of Akt to inhibit apoptosis because glucose uptake plays a critical role in regulating intracellular ATP levels and cell viability. Akt could also mediate the
increase in GLUT1 gene expression that follows hypoxia
because such conditions can activate the PI 3-kinase/Akt pathway (40). However, we did not find that the PI 3-kinase inhibitor, LY294002, could block the hypoxia-induced GLUT1 mRNA accumulation. Thus, one
of the roles of Akt in the maintenance of cellular homeostasis may be
to integrate several types of environmental stimuli, leading to
enhanced expression of a subset of genes, including
GLUT1.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-actin probes were from Operon Technologies Inc. (Alameda, CA), and the pGEM-T vector system was from
Promega (Madison, WI). [
-32P]ATP (3000 Ci/mmol) was
from NEN Life Science Products, and the random priming kit,
[
-32P]UTP (800 Ci/mmol), [
-32P]dCTP
(3000 Ci/mmol), and horseradish peroxidase-conjugated secondary antibody were from Amersham Pharmacia Biotech. The Akt-substrate peptide was synthesized in the Beckman PAN facility (Stanford, CA).
Anti-GLUT1 polyclonal antiserum was from East Acres (Southbridge, MA),
acrylamide was from National Diagnostics (Atlanta, GA), nitrocellulose and nylon membranes were from Schleicher & Schuell, insulin and anti-HA
monoclonal antibody (12CA5) were from Roche Molecular Biochemicals, and
anti-Akt1 antibodies (directed against the C terminus) were from
Upstate Biochemicals (Lake Placid, NY). Anti-Akt1 and Akt3 antibodies
directed against their respective pleckstrin homology domains were
produced as described (23). Anti-Akt2 antibodies were a gift of Dr.
Birnbaum (University of Pennsylvania) (24). Sephadex 10 microspin
columns were from Amersham Pharmacia Biotech, and Express-Hyb solution
was from CLONTECH (Palo Alto, CA). Protein
A-Sepharose was from Repligen (Cambridge, MA). Protein determination
was performed using the BCA kit (Pierce). 4-Hydroxytamoxifen and all
other chemicals were from Sigma.
-minimum Eagle's medium
containing 10% (v/v) fetal calf serum, 100 µg/ml streptomycin, and
100 units/ml penicillin. After reaching confluency, the cells were put
in serum-free
-minimum Eagle's medium supplemented with 0.1 mg/ml
bovine serum albumin, 20 mM Hepes, pH 7.4, penicillin/streptomycin and treated. In some cases, cells were
subjected to hypoxic conditions by placing them in a humidified
automatic CO2/O2 incubator (Forma Scientific, model 3159) maintained at 37 °C and 1% O2, 5%
CO2, and 94% N2.
32-P]ATP on a 40% polyacrylamide gel containing 6 M urea. The phosphopeptide spots were excised and counted.
-Actin Probes--
cDNA from
total Hepa1c1c7 cell RNA was made by reverse transcription using
oligo-dT as primer. A 1479-base pair GLUT1 fragment was
amplified by polymerase chain reaction using the sequences 5'-ATG GAT
CCC AGC AGC AAG AAG GTG A-3' and 5'-TCA CAC TTG GGA GTC CGC CCC GAG
A-3' as primer; for
-actin, a 540-base pair spanning fragment was
generated utilizing 5'-GTG GGC CGC TCT AGG CAC CAA-3' and 5'-CTC TTT
GAT GTC ACG CAC GAT TTC-3', respectively. For the Northern blots, 20 ng
of the GLUT1 or actin cDNAs were random primed with 50 µCi of [
32-P]dCTP. For the nuclear run-on assays,
the actin and GLUT1-polymerase chain reaction fragments were
gel-purified and subcloned into the pGEM-T vector using the TA cloning
kit from Promega.
80 °C. To perform transcriptional run-ons, 100 µl of the nuclear preparation were mixed with 50 µl of
3× transcription buffer (50 mM Tris, pH 8.1; 210 mM KCl; 3 mM MgCl2; 3 mM dithiothreitol; 2.4 mM of each ATP, GTP, and CTP; 1 µCi/µl [
32-P]UTP; and 200 units/ml RNAsin).
The mixture was incubated at 30 °C for 30 min. Total RNA was
isolated by treating the mixture with DNase I (10 units for 30 min at
37 °C) and then proteinase K (50 µg for 1 h at 37 °C) and
then extracting with phenol/chloroform. Free unincorporated nucleotides
were separated from the RNA with a Sephadex-10 spin column. The RNA was
fragmented into smaller pieces (300-600 bases in length) by incubation
in 200 mM NaOH for 5-10 min at 4 °C and precipitated
with ethanol. Hybridization of the RNA (approximately 1 × 106 cpm/ml) to the filter bound actin and
GLUT1 probes in the pGEM-T vector (2 µg DNA/slot) was
performed at 65 °C for 60 h in Express-Hyb solution. The
filters were then washed at least four times at 65 °C in 2×
SSC/0.1% SDS and two more times in 0.2× SSC/0.1% SDS before they
were exposed to the film. The blots were visualized by autoradiography
and quantified using a PhosphorImager and the Imagequant software
(Molecular Dynamics).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (14K):
[in a new window]
Fig. 1.
Insulin induces Akt1 activity and GLUT1
mRNA accumulation in a concentration-dependent
fashion. A, Akt1 activity. Hepa1c1c7 cells were
serum-starved overnight, incubated for 30 min with the indicated
insulin concentration, and lysed; endogenous Akt1 was
immunoprecipitated and assayed for enzymatic activity using
GSK3-peptide as substrate. Bars indicate the means (± S.E.)
of three experiments. B, GLUT1 mRNA. Hepa1c1c7 cells
were treated with the indicated concentration of insulin for 18 h
and lysed; total RNA was isolated and assayed for GLUT1 and actin
mRNA by Northern analysis. The autoradiograms from three
experiments were scanned, normalized for the amounts of actin present,
and expressed as the fold induction over the nontreated controls.

View larger version (22K):
[in a new window]
Fig. 2.
Time course of Akt activation.
A, activation of MER-Akt1 by hydroxytamoxifen. Cells were
treated with 1 µM hydroxytamoxifen for the indicated
periods of time and lysed, and the expressed HA-tagged MER-Akt1 was
immunoprecipitated and assayed for enzyme activity. Data
points indicate the means (± S.E.) of three experiments. The
inset in A shows a Western blot of total cell
lysate (10 µg of protein) obtained from cells infected with either
empty retroviral vector (lane 1) or vector encoding MER-Akt1
(lane 2) probed with anti-Akt1 antibody. The higher
molecular mass protein is the MER-Akt1, and the smaller protein is the
endogenous Akt1. B, activation of endogenous Akt by insulin.
Cells were treated with 1 µM insulin for the indicated
periods of time and lysed, and endogenous Akt1 was immunoprecipitated
and assayed for enzyme activity. Data points indicate the
means (± S.E.) of three experiments. The inset in
B shows the results of an assay for the insulin-stimulated
endogenous Akt3.

View larger version (32K):
[in a new window]
Fig. 3.
Insulin and Akt both induce Glut1 mRNA
and protein in Hepa1c1c7 cells. A, GLUT1 protein and
mRNA induction by insulin and Akt. Cells infected with the empty
retroviral vector (pWZL-neo) or cells stably expressing MER-Akt1 were
incubated for 18 h with ethanol (as control), insulin (1 µM), or hydroxytamoxifen (1 µM). The cells
were then lysed, and membrane proteins or total RNA was purified from
the lysates. The top panel shows a Western blot of 10 µg
of membrane protein probed with anti-Glut1-antibody. The middle
panel shows an autoradiograph of a Northern blot probed for GLUT1
mRNA. The bottom panel shows a Northern blot probed for
actin (as a control). B, time course of GLUT1 protein;
C, time course of mRNA induction. Hepa cells expressing
MER-Akt1 were stimulated with 1 µM hydroxytamoxifen for
the times indicated, lysed, and analyzed for either GLUT1 protein or
GLUT1 and actin mRNA, as described under "Experimental
Procedures." The GLUT1 protein and mRNA levels (after
normalization for the amounts of actin present) are expressed as the
percentage of the highest values observed (at 24 and 48 h of
treatment for the protein and mRNA, respectively). Results shown
are representative of three experiments.

View larger version (27K):
[in a new window]
Fig. 4.
Concentration dependence of
hydroxytamoxifen-stimulated MER-Akt1 activity and GLUT1 mRNA
accumulation in Hepa1c1c7 cells. Hepa1c1c7 cells stably expressing
MER-Akt1 were serum-starved overnight and stimulated for 2 h (for
Akt activity) or 18 h (for GLUT1 mRNA) with the indicated
concentrations of hydroxytamoxifen. Cells were lysed and assayed for
either MER-Akt1 activity (A) or GLUT1 mRNA
(B) as described under "Experimental Procedures."
Data points indicate the means (± S.E.) of three
experiments.

View larger version (28K):
[in a new window]
Fig. 5.
Effect of a kinase inactive Akt1 on the
insulin-stimulated GLUT1 mRNA accumulation in Hepa1c1c7 cells.
A, expression of an inactive Akt1. Hepa1c1c7 cells were
infected with either the empty retroviral vector or a retroviral vector
encoding an inactive Akt1 mutant (Akt1-S473A/T308A-pWZL-neo). Amounts
of the mutant Akt1 were determined by Western blotting of total cell
lysates (10 µg/lane) from control cells (lane 1) and from
cells infected with mutant Akt1 (lane 2). B,
effect of inactive Akt1 on induction of GLUT1 mRNA by insulin.
Hepa1c1c7 cells infected with either the empty retroviral vector (pWZL)
or inactive Akt1 (Akt1-S473A/T308A-pWZL-neo) were serum-starved and
treated for 18 h with the indicated concentrations of insulin. The
cells were lysed, and total RNA was assayed for GLUT1 and actin
mRNA by Northern analysis. The results were quantitated and are
presented as fold inductions (± S.E.). Black bars represent
data from the noninfected cells; gray bars represent the
data from cells expressing inactive Akt1. Numbers in
parentheses represent the number of experiments performed at
the indicated insulin concentrations.

View larger version (25K):
[in a new window]
Fig. 6.
Effect of insulin and hydroxytamoxifen on the
half-life of GLUT1 mRNA. Hepa1c1c7 cells expressing MER-Akt1
were exposed to ethanol (as control) (A), insulin (1 µM) (B), or hydroxytamoxifen (1 µM) (C) in the presence of actinomycin D (5 µg/ml). Cells were harvested after 0, 3, or 6 h, and total RNA
was assayed for GLUT1 and actin mRNA by blot hybridization. The
autoradiograms shown are representative of three experiments. The
amounts of GLUT1 and actin mRNA were quantified by phosphorimaging;
the GLUT1 mRNA was normalized to actin and expressed as the
percentage of GLUT1 mRNA at time 0. The values shown are means (± S.E.) of three experiments.

View larger version (10K):
[in a new window]
Fig. 7.
Nuclear run-on experiments. Hepa1c1c7
cells expressing MER-Akt1 were exposed to ethanol (as a control),
insulin (1 µM), or hydroxytamoxifen (1 µM).
The cells were lysed, nuclei were isolated, and transcriptional run-on
assays were performed as described under "Experimental Procedures."
The radiolabeled mRNA was hybridized with immobilized DNA probes
for GLUT1 and actin. The autoradiograms from three experiments were
scanned, normalized for the amounts of actin present, and expressed as
the fold induction over the nontreated controls.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
and the aryl hydrocarbon receptor nuclear
translocator (37). Akt could phosphorylate these transcription factors,
thus influencing their interactions with each other or with DNA. A third possibility is that Akt could phosphorylate a cytoplasmic factor(s), thereby allowing the release of an associated transcription factor, as described for I
B kinase and activation of NF-
B (38). In addition, recent genetic studies have identified a forkhead transcription factor, DAF-16, that functions downstream of Akt in
Caenorhabditis elegans (39). Therefore, Akt might
mediate GLUT1 transcription via regulating a mammalian
homolog of DAF-16. These appear to be interesting areas for future research.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Dr. Garry Nolan for the Phoenix retroviral packaging cell line and the retroviral vectors, Dr. Morris Birnbaum for the antibodies to Akt2, and Dr. Karlene Cimprich for a critical reading of the manuscript.
| |
FOOTNOTES |
|---|
* This work was supported in part by National Institutes of Health Grants DK 34926 (to R. A. R.) and ES08655 (to J. P. W.), an American Diabetes Association Mentor-Based Postdoctoral Fellowship (to K. N.), and a Feodor-Lynen Fellowship of the Alexander von Humboldt-Stiftung (to A. B.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of Molecular
Pharmacology, Stanford Medical Center, Stanford, CA 94305. Tel.:
650-723-5933; Fax: 650-725-2952; E-mail: rroth@stanford.edu.
2 A. Barthel, S. T. Okino, J. Liao, K. Nakatani, J. Li, J. P. Whitlock, Jr., and R. A. Roth, unpublished observations.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: GLUT, glucose transporter; MER-Akt, myristoylated Akt estrogen receptor chimera; HA, hemagglutinin; PI, phosphatidylinositol.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Mueckler, M., Hresko, R. C., and Sato, M. (1997) Biochem. Soc. Trans. 25, 951-954[Medline] [Order article via Infotrieve] |
| 2. | Olson, A. L., and Pessin, J. E. (1996) Annu. Rev. Nutr. 16, 235-256[CrossRef][Medline] [Order article via Infotrieve] |
| 3. | Holman, G. D., and Cushman, S. W. (1994) BioEssays 16, 753-759[CrossRef][Medline] [Order article via Infotrieve] |
| 4. |
Garcia de Herreros, A.,
and Birnbaum, M. J.
(1989)
J. Biol. Chem.
264,
19994-19999 |
| 5. |
Walker, P. S.,
Ramlal, T.,
Donovan, J. A.,
Doering, T. P.,
Sandra, A.,
Klip, A.,
and Pessin, J. E.
(1989)
J. Biol. Chem.
264,
6587-6595 |
| 6. |
Bashan, N.,
Burdett, E.,
Hundal, H. S.,
and Klip, A.
(1992)
Am. J. Physiol.
262,
C682-C690 |
| 7. |
Kozlovsky, N.,
Rudich, A.,
Potashnik, R.,
Ebina, Y.,
Murakami, T.,
and Bashan, N.
(1997)
J. Biol. Chem.
272,
33367-33372 |
| 8. |
Behrooz, A.,
and Ismail-Beigi, F.
(1997)
J. Biol. Chem.
272,
5555-5562 |
| 9. | Lee, W. H., and Bondy, C. A. (1993) Endocrinology 133, 2540-2544[Abstract] |
| 10. |
Birnbaum, M. J.,
Haspel, H. C.,
and Rosen, O. M.
(1987)
Science
235,
1495-1498 |
| 11. |
Hiraki, Y.,
Garcia de Herreros, A.,
and Birnbaum, M. J.
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
8252-8256 |
| 12. |
Flier, J. S.,
Mueckler, M. M.,
Usher, P.,
and Lodish, H. F.
(1987)
Science
235,
1492-1495 |
| 13. | Shepherd, P. R., Withers, D. J., and Siddle, K. (1998) Biochem. J. 333, 471-490 |
| 14. | Robinson, M. J., and Cobb, M. H. (1997) Curr. Opin. Cell Biol. 9, 180-186[CrossRef][Medline] [Order article via Infotrieve] |
| 15. | Toker, A., and Cantley, L. C. (1997) Nature 387, 673-676[CrossRef][Medline] [Order article via Infotrieve] |
| 16. | Coffer, P. J., Jin, J., and Woodgett, J. R. (1998) Biochem. J. 335, 1-13 |
| 17. |
O'Brien, R. M.,
and Granner, D. K.
(1996)
Physiol. Rev.
76,
1109-1161 |
| 18. |
Wang, D.,
and Sul, H. S.
(1998)
J. Biol. Chem.
273,
25420-25426 |
| 19. |
Cichy, S. B.,
Uddin, S.,
Danilkovich, A.,
Guo, S.,
Klippel, A.,
and Unterman, T. G.
(1998)
J. Biol. Chem.
273,
6482-6487 |
| 20. |
Liao, J.,
Barthel, A.,
Nakatani, K.,
and Roth, R. A.
(1998)
J. Biol. Chem.
273,
27320-27324 |
| 21. |
Agati, J. M.,
Yeagley, D.,
and Quinn, P. G.
(1998)
J. Biol. Chem.
273,
18751-18759 |
| 22. |
Dickens, M.,
Svitek, C. A.,
Culbert, A. A.,
O'Brien, R. M.,
and Tavare, J. M.
(1998)
J. Biol. Chem.
273,
20144-20149 |
| 23. | Krook, A., Kawano, Y., Song, X. M., Efendic, S., Roth, R. A., Wallberg-Henriksson, H., and Zierath, J. R. (1997) Diabetes 46, 2110-2114[Abstract] |
| 24. |
Calera, M. R.,
Martinez, C.,
Liu, H.,
El Jack, A. K.,
Birnbaum, M. J.,
and Pilch, P. F.
(1998)
J. Biol. Chem.
273,
7201-7204 |
| 25. |
Kohn, A. D.,
Barthel, A.,
Kovacina, K. S.,
Boge, A.,
Wallach, B.,
Summers, S. A.,
Birnbaum, M. J.,
Scott, P. H.,
Lawrence, J. C., Jr.,
and Roth, R. A.
(1998)
J. Biol. Chem.
273,
11937-11943 |
| 26. |
Todaka, M.,
Nishiyama, T.,
Murakami, T.,
Saito, S.,
Ito, K.,
Kanai, F.,
Kan, M.,
Ishii, K.,
Hayashi, H.,
Shichiri, M.,
and Ebina, Y.
(1994)
J. Biol. Chem.
269,
29265-29270 |
| 27. | Walker, K. S., Deak, M., Paterson, A., Hudson, K., Cohen, P., and Alessi, D. R. (1998) Biochem. J. 331, 299-308 |
| 28. |
Kohn, A. D.,
Summers, S. A.,
Birnbaum, M. J.,
and Roth, R. A.
(1996)
J. Biol. Chem.
271,
31372-31378 |
| 29. | Hajduch, E., Alessi, D. R., Hemmings, B. A., and Hundal, H. S. (1998) Diabetes 47, 1006-1013[Abstract] |
| 30. |
Hausdorff, S.,
Frangioni, J.,
and Birnbaum, M.
(1994)
J. Biol. Chem.
269,
21391-21394 |
| 31. |
Liu, A. X.,
Testa, J. R.,
Hamilton, T. C.,
Jove, R.,
Nicosia, S. V.,
and Cheng, J. Q.
(1998)
Cancer Res.
58,
2973-2977 |
| 32. |
Somwar, R.,
Sumitani, S.,
Taha, C.,
Sweeney, G.,
and Klip, A.
(1998)
Am. J. Physiol.
275,
E618-E625 |
| 33. |
Scott, P. H.,
Brunn, G. J.,
Kohn, A. D.,
Roth, R. A.,
and Lawrence, J. C., Jr.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
7772-7777 |
| 34. |
Taha, C.,
Mitsumoto, Y.,
Liu, Z.,
Skolnik, E. Y.,
and Klip, A.
(1995)
J. Biol. Chem.
270,
24678-24681 |
| 35. |
Vlahos, C. J.,
Matter, W. F.,
Hui, K. Y.,
and Brown, R. F.
(1994)
J. Biol. Chem.
269,
5241-5248 |
| 36. |
Du, K.,
and Montminy, M.
(1998)
J. Biol. Chem.
273,
32377-32379 |
| 37. | Zelzer, E., Levy, Y., Kahana, C., Shilo, B. Z., Rubinstein, M., and Cohen, B. (1998) EMBO J. 17, 5085-5094[CrossRef][Medline] [Order article via Infotrieve] |
| 38. | Stancovski, I., and Baltimore, D. (1997) Cell 91, 299-302[CrossRef][Medline] [Order article via Infotrieve] |
| 39. |
Paradis, S.,
and Ruvkun, G.
(1998)
Genes Dev.
12,
2488-2498 |
| 40. |
Mazure, N. M.,
Chen, E. Y.,
Laderoute, K. R.,
and Giaccia, A. J.
(1997)
Blood
90,
3322-3331 |
This article has been cited by other articles:
![]() |
S. R. Jacobs, C. E. Herman, N. J. MacIver, J. A. Wofford, H. L. Wieman, J. J. Hammen, and J. C. Rathmell Glucose Uptake Is Limiting in T Cell Activation and Requires CD28-Mediated Akt-Dependent and Independent Pathways J. Immunol., April 1, 2008; 180(7): 4476 - 4486. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Dongiovanni, L. Valenti, A. Ludovica Fracanzani, S. Gatti, G. Cairo, and S. Fargion Iron Depletion by Deferoxamine Up-Regulates Glucose Uptake and Insulin Signaling in Hepatoma Cells and in Rat Liver Am. J. Pathol., March 1, 2008; 172(3): 738 - 747. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. De Riva, C. Bourgeois, G. Kassiotis, and B. Stockinger Noncognate Interaction with MHC Class II Molecules Is Essential for Maintenance of T Cell Metabolism to Establish Optimal Memory CD4 T Cell Function J. Immunol., May 1, 2007; 178(9): 5488 - 5495. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. L. Wieman, J. A. Wofford, and J. C. Rathmell Cytokine Stimulation Promotes Glucose Uptake via Phosphatidylinositol-3 Kinase/Akt Regulation of Glut1 Activity and Trafficking Mol. Biol. Cell, April 1, 2007; 18(4): 1437 - 1446. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Swainson, S. Kinet, C. Mongellaz, M. Sourisseau, T. Henriques, and N. Taylor IL-7-induced proliferation of recent thymic emigrants requires activation of the PI3K pathway Blood, February 1, 2007; 109(3): 1034 - 1042. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Schiekofer, I. Shiojima, K. Sato, G. Galasso, Y. Oshima, and K. Walsh Microarray analysis of Akt1 activation in transgenic mouse hearts reveals transcript expression profiles associated with compensatory hypertrophy and failure Physiol Genomics, October 11, 2006; 27(2): 156 - 170. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. V. Parry, J. M. Chemnitz, K. A. Frauwirth, A. R. Lanfranco, I. Braunstein, S. V. Kobayashi, P. S. Linsley, C. B. Thompson, and J. L. Riley CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms Mol. Cell. Biol., November 1, 2005; 25(21): 9543 - 9553. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hahn-Windgassen, V. Nogueira, C.-C. Chen, J. E. Skeen, N. Sonenberg, and N. Hay Akt Activates the Mammalian Target of Rapamycin by Regulating Cellular ATP Level and AMPK Activity J. Biol. Chem., September 16, 2005; 280(37): 32081 - 32089. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Schinner, A. Barthel, C. Dellas, R. Grzeskowiak, S. K. Sharma, E. Oetjen, R. Blume, and W. Knepel Protein Kinase B Activity Is Sufficient to Mimic the Effect of Insulin on Glucagon Gene Transcription J. Biol. Chem., February 25, 2005; 280(8): 7369 - 7376. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Arsham, D. R. Plas, C. B. Thompson, and M. C. Simon Akt and Hypoxia-Inducible Factor-1 Independently Enhance Tumor Growth and Angiogenesis Cancer Res., May 15, 2004; 64(10): 3500 - 3507. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Frauwirth and C. B. Thompson Regulation of T Lymphocyte Metabolism J. Immunol., April 15, 2004; 172(8): 4661 - 4665. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Roth, K. Curth, T. G. Unterman, and T. Kietzmann The Transcription Factors HIF-1 and HNF-4 and the Coactivator p300 Are Involved in Insulin-regulated Glucokinase Gene Expression via the Phosphatidylinositol 3-Kinase/Protein Kinase B Pathway J. Biol. Chem., January 23, 2004; 279(4): 2623 - 2631. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Rathmell, C. J. Fox, D. R. Plas, P. S. Hammerman, R. M. Cinalli, and C. B. Thompson Akt-Directed Glucose Metabolism Can Prevent Bax Conformation Change and Promote Growth Factor-Independent Survival Mol. Cell. Biol., October 15, 2003; 23(20): 7315 - 7328. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Yim, S. M. Choi, Y. Choi, N. Lee, J. Chung, and H. Park Insulin and Hypoxia Share Common Target Genes but Not the Hypoxia-inducible Factor-1{alpha} J. Biol. Chem., October 3, 2003; 278(40): 38260 - 38268. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. L. Schwertfeger, J. L. McManaman, C. A. Palmer, M. C. Neville, and S. M. Anderson Expression of constitutively activated Akt in the mammary gland leads to excess lipid synthesis during pregnancy and lactation J. Lipid Res., June 1, 2003; 44(6): 1100 - 1112. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Pirola, S. Bonnafous, A. M. Johnston, C. Chaussade, F. Portis, and E. Van Obberghen Phosphoinositide 3-Kinase-mediated Reduction of Insulin Receptor Substrate-1/2 Protein Expression via Different Mechanisms Contributes to the Insulin-induced Desensitization of Its Signaling Pathways in L6 Muscle Cells J. Biol. Chem., April 25, 2003; 278(18): 15641 - 15651. [Abstract] [Full Text] [PDF] |
||||